Cowen and Company reissued their outperform rating on shares of Humana Inc. (NYSE:HUM) in a research report report published on Wednesday. They currently have a $275.00 target price on the insurance provider’s stock, up from their prior target price of $230.00.

A number of other brokerages have also commented on HUM. UBS AG reissued a neutral rating and set a $250.00 price objective (up previously from $237.00) on shares of Humana in a report on Wednesday, August 9th. Zacks Investment Research lowered shares of Humana from a hold rating to a sell rating in a report on Thursday, July 27th. BidaskClub raised shares of Humana from a sell rating to a hold rating in a report on Thursday, August 10th. Cantor Fitzgerald reissued a neutral rating and set a $223.00 price objective (up previously from $200.00) on shares of Humana in a report on Thursday, August 3rd. Finally, Jefferies Group LLC reissued a hold rating and set a $257.00 price objective on shares of Humana in a report on Friday, August 4th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and thirteen have given a buy rating to the stock. Humana presently has a consensus rating of Buy and a consensus price target of $246.60.

Shares of Humana (HUM) opened at 239.09 on Wednesday. The company has a market capitalization of $34.55 billion, a P/E ratio of 19.67 and a beta of 0.87. Humana has a 52-week low of $163.50 and a 52-week high of $259.76. The firm’s 50 day moving average is $250.95 and its 200-day moving average is $232.23.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, August 2nd. The insurance provider reported $3.49 EPS for the quarter, topping analysts’ consensus estimates of $3.08 by $0.41. Humana had a net margin of 3.37% and a return on equity of 15.85%. The firm had revenue of $13.53 billion for the quarter, compared to analyst estimates of $13.61 billion. During the same quarter in the prior year, the firm earned $2.30 EPS. Equities research analysts anticipate that Humana will post $11.55 earnings per share for the current fiscal year.

WARNING: This article was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.thecerbatgem.com/2017/09/24/cowen-and-company-reiterates-outperform-rating-for-humana-inc-hum.html.

The company also recently declared a quarterly dividend, which will be paid on Friday, October 27th. Investors of record on Tuesday, August 29th will be given a $0.40 dividend. The ex-dividend date is Thursday, September 28th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.67%. Humana’s dividend payout ratio is 13.06%.

In related news, SVP Brian P. Leclaire sold 4,971 shares of the stock in a transaction that occurred on Wednesday, June 28th. The shares were sold at an average price of $240.00, for a total value of $1,193,040.00. Following the sale, the senior vice president now directly owns 14,258 shares in the company, valued at approximately $3,421,920. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP M Todoroff Christopher sold 22,935 shares of the stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $252.52, for a total transaction of $5,791,546.20. Following the completion of the sale, the vice president now owns 24,001 shares in the company, valued at $6,060,732.52. The disclosure for this sale can be found here. Insiders sold a total of 60,566 shares of company stock worth $15,326,746 over the last quarter. 0.80% of the stock is currently owned by corporate insiders.

Large investors have recently made changes to their positions in the stock. WFG Advisors LP raised its position in shares of Humana by 4.5% in the 2nd quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock valued at $113,000 after acquiring an additional 20 shares during the period. Acrospire Investment Management LLC acquired a new stake in Humana during the 2nd quarter worth approximately $120,000. Independent Portfolio Consultants Inc. raised its holdings in Humana by 22.1% during the 2nd quarter. Independent Portfolio Consultants Inc. now owns 519 shares of the insurance provider’s stock worth $125,000 after buying an additional 94 shares during the period. Northwestern Mutual Wealth Management Co. raised its holdings in Humana by 139.5% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 558 shares of the insurance provider’s stock worth $134,000 after buying an additional 325 shares during the period. Finally, Fiduciary Trust Co. acquired a new stake in Humana during the 2nd quarter worth approximately $135,000. Institutional investors and hedge funds own 95.12% of the company’s stock.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Stock Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related stocks with our FREE daily email newsletter.